Lizhu Pharmaceutical (01513) announced interim results, net profit of 932 million yuan decreased by 27.23% year on year

According to the Zhitong Finance App, Lizhu Pharmaceutical (01513) announced results for the six months ended June 30, 2026. The group achieved operating income of about RMB 5 billion, a year-on-year decrease of 20.28%; net profit attributable to shareholders of the parent company was RMB 932 million, a year-on-year decrease of 27.23%; and basic income per share was RMB 1.05.

During the reporting period, the Group's chemical formulation segment achieved sales revenue of RMB 2,442 billion, a decrease of 25.33% over the same period last year. The main influencing factors include: key varieties of iprazole sodium series, injectable urotropin, etc. were affected by medical insurance price cuts, and sales revenue declined; sales revenue for injectable leuprorelin declined sharply in the Guangdong Union region; the spiritual product fluvoxamine maleate began to be collected in the 11th batch of national collections this year, and sales revenue declined.

During the reporting period, the Group's APIs and intermediates business achieved sales revenue of RMB 1,611 billion, down 3.04% from the same period last year. The main influencing factors include: the overall domestic API is still at the bottom of the cycle and structural repair stage, and total domestic sales of APIs declined slightly; however, the export business, which mainly focuses on specialty APIs, showed strong resilience. Among them, high-end antibiotics and intermediates showed impressive performance, effectively hedging the phased pressure on the domestic market, driving the API sector's gross margin and profit level to remain stable.

During the reporting period, the Group's traditional Chinese medicine formulation segment achieved sales revenue of RMB 521 million, a decrease of 34.83% over the same period of the previous year; diagnostic reagents, equipment, biological products, etc. achieved total sales revenue of 426 million yuan, a decrease of 21.25% over the same period last year. The main influencing factors include: In the first quarter of 2026, the incidence rate of influenza and respiratory diseases in China declined compared to the same period in 2025, and the Group's revenue from antiviral granules and respiratory related products in the diagnostic sector declined year-on-year.